Wedbush Issues Pessimistic Estimate for RVMD Earnings

Key Takeaways:

• Wedbush has cut Revolution Medicines’ anticipated earnings for FY2029.
• The revised estimate stands at $1.23 per share, down from $1.47.
• Wedbush analyst R. Driscoll reported the change on September 11th.
• Revolution Medicines is traded under NASDAQ: RVMD.
• The story was published by Americanbankingnews on September 13, 2025.

Wedbush’s Revised Forecast

A recent research note from Wedbush has sent a wave of caution through followers of Revolution Medicines, Inc. (NASDAQ: RVMD). In that note, published on Thursday, September 11th, Wedbush outlined a less optimistic view of the company’s projected performance.

The Shift in Numbers

At the heart of this update is Wedbush analyst R. Driscoll’s decision to cut the biotech firm’s expected 2029 earnings per share. The new figure, $1.23, is noticeably lower than the earlier estimate of $1.47. While no additional context was provided, this adjustment underscores a recalibrated perspective of Revolution Medicines’ future financials.

Implications for Revolution Medicines

Revolution Medicines, as a biotechnology company, relies heavily on investor confidence and solid projections. A downward revision of earnings estimates often prompts closer scrutiny from shareholders, though official commentary from Revolution Medicines itself is not included in the research note excerpt.

Context Behind the Report

Wedbush’s updated assessment was issued just two days before the publication of this story in Americanbankingnews on September 13, 2025. The timing highlights the swift communication between research analysts and the broader financial community when projections change.

Looking Ahead

While the revised numbers indicate a more conservative view of Revolution Medicines’ earnings, the company’s performance will ultimately be shaped by its internal growth, clinical milestones, and market factors. For now, Wedbush’s new estimate serves as a reminder of the ever-evolving nature of biotech forecasts.